Omar Hasan Ali

1.9k total citations
20 papers, 704 citations indexed

About

Omar Hasan Ali is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Omar Hasan Ali has authored 20 papers receiving a total of 704 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 6 papers in Molecular Biology and 5 papers in Immunology. Recurrent topics in Omar Hasan Ali's work include Cancer Immunotherapy and Biomarkers (12 papers), Colorectal Cancer Treatments and Studies (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Omar Hasan Ali is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Colorectal Cancer Treatments and Studies (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Omar Hasan Ali collaborates with scholars based in Switzerland, Germany and United States. Omar Hasan Ali's co-authors include Lukas Flatz, David Bomze, Stefan Diem, Wolfram Jochum, Martin Früh, Andrew Bate, Fiamma Berner, Mirjam Fässler, Antonio Cozzio and Daniel E. Speiser and has published in prestigious journals such as Clinical Infectious Diseases, Journal of the American Academy of Dermatology and European Journal of Cancer.

In The Last Decade

Omar Hasan Ali

19 papers receiving 699 citations

Peers

Omar Hasan Ali
Krista M. Rubin United States
Kelsey L. Corrigan United States
Kahaku Emoto Japan
Troy Z. Horvat United States
Seong Hyun Jeong South Korea
N. J. Vogelzang United States
Aya Nakaya Japan
Yunfei Wang United States
Lucia Bonomi Italy
Eléonora De Martin France
Krista M. Rubin United States
Omar Hasan Ali
Citations per year, relative to Omar Hasan Ali Omar Hasan Ali (= 1×) peers Krista M. Rubin

Countries citing papers authored by Omar Hasan Ali

Since Specialization
Citations

This map shows the geographic impact of Omar Hasan Ali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Omar Hasan Ali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Omar Hasan Ali more than expected).

Fields of papers citing papers by Omar Hasan Ali

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Omar Hasan Ali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Omar Hasan Ali. The network helps show where Omar Hasan Ali may publish in the future.

Co-authorship network of co-authors of Omar Hasan Ali

This figure shows the co-authorship network connecting the top 25 collaborators of Omar Hasan Ali. A scholar is included among the top collaborators of Omar Hasan Ali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Omar Hasan Ali. Omar Hasan Ali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Flatz, Lukas, Omar Hasan Ali, Raphael Mohr, et al.. (2025). HLA-A*01:01-B*08:01-C*07:01 is linked to early-onset immune checkpoint inhibitor-induced myositis and myocarditis. Journal for ImmunoTherapy of Cancer. 13(9). e011590–e011590.
2.
Tomlinson, Julianna J., Jonas Franz, Omar Hasan Ali, et al.. (2024). Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19. Acta Neuropathologica Communications. 12(1). 70–70. 1 indexed citations
3.
Gómez, Julia M. Martínez, Patrick Turko, Egle Ramelyte, et al.. (2024). Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in Switzerland. Cancers. 16(5). 854–854. 2 indexed citations
4.
Purde, Mette-Triin, Rebekka Niederer, Nikolaus B. Wagner, et al.. (2021). Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. Journal of Cancer Research and Clinical Oncology. 148(3). 647–656. 11 indexed citations
5.
Ali, Omar Hasan, David Bomze, Lorenz Risch, et al.. (2020). Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. Clinical Infectious Diseases. 73(9). e2869–e2874. 69 indexed citations
6.
Ring, Sandra S., Erika Schmidt, Omar Hasan Ali, et al.. (2020). Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8+ T Cell Responses. Molecular Therapy — Oncolytics. 19. 179–187. 5 indexed citations
7.
Ali, Omar Hasan, Andrey A. Yurchenko, Olga Pavlova, et al.. (2020). Genomic profiling of late‐onset basal cell carcinomas from two brothers with nevoid basal cell carcinoma syndrome. Journal of the European Academy of Dermatology and Venereology. 35(2). 396–402. 2 indexed citations
8.
Bomze, David, Tomer Meirson, Omar Hasan Ali, et al.. (2020). Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis. Ocular Immunology and Inflammation. 30(1). 191–197. 39 indexed citations
9.
Ali, Omar Hasan, Fiamma Berner, Christoph Ackermann, et al.. (2020). Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. Cancer Immunology Immunotherapy. 70(2). 563–568. 6 indexed citations
10.
Bomze, David, Nethanel Asher, Omar Hasan Ali, et al.. (2020). Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors. JAMA Network Open. 3(10). e2017675–e2017675. 22 indexed citations
11.
Ali, Omar Hasan, David Bomze, Sandra S. Ring, et al.. (2019). BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. Journal of the American Academy of Dermatology. 82(4). 854–861. 76 indexed citations
12.
Bomze, David, Omar Hasan Ali, Andrew Bate, & Lukas Flatz. (2019). Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden. JAMA Oncology. 5(11). 1633–1633. 98 indexed citations
13.
Diem, Stefan, Mirjam Fässler, David Bomze, et al.. (2019). Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. Journal of Immunotherapy. 42(3). 89–93. 24 indexed citations
14.
Diem, Stefan, Mirjam Fässler, Omar Hasan Ali, et al.. (2018). Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. Cancer Management and Research. Volume 10. 5537–5544. 2 indexed citations
15.
Ali, Omar Hasan, Fiamma Berner, David Bomze, et al.. (2018). Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. European Journal of Cancer. 107. 8–14. 143 indexed citations
16.
Fischer, Stefanie, et al.. (2018). Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma. Oncology Research and Treatment. 41(6). 391–394. 40 indexed citations
17.
Simon, Dagmar, Stephan Nobbe, Mirjam Nägeli, et al.. (2018). Short- and long-term effects of two emollients on itching and skin restoration in xerotic eczema. Dermatologic Therapy. 31(6). e12692–e12692. 16 indexed citations
18.
Betschart, Patrick, Valentin Zumstein, Omar Hasan Ali, Hans‐Peter Schmid, & Dominik Abt. (2017). Readability Assessment of Patient Education Material Published by German-Speaking Associations of Urology. Urologia Internationalis. 100(1). 79–84. 9 indexed citations
19.
Diem, Stefan, Omar Hasan Ali, Christoph Ackermann, et al.. (2017). Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. Cancer Immunology Immunotherapy. 67(1). 39–45. 40 indexed citations
20.
Ali, Omar Hasan, Stefan Diem, Eva Markert, et al.. (2016). Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. OncoImmunology. 5(11). e1231292–e1231292. 99 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Krista M. Rubin Breakdown of academic impact, for papers by Kelsey L. Corrigan Breakdown of academic impact, for papers by Kahaku Emoto Breakdown of academic impact, for papers by Troy Z. Horvat Breakdown of academic impact, for papers by Seong Hyun Jeong Breakdown of academic impact, for papers by N. J. Vogelzang Breakdown of academic impact, for papers by Aya Nakaya Breakdown of academic impact, for papers by Yunfei Wang Breakdown of academic impact, for papers by Lucia Bonomi Breakdown of academic impact, for papers by Eléonora De Martin
Rankless by CCL
2026